Related references
Note: Only part of the references are listed.Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy
Erwin A. van Vliet et al.
EPILEPSIA (2009)
Complement activation in experimental and human temporal lobe epilepsy
E. Aronica et al.
NEUROBIOLOGY OF DISEASE (2007)
Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management
Melanie S. M. van Breemen et al.
LANCET NEUROLOGY (2007)
Inhibitory networks in epilepsy-associated gangliogliomas and in the perilesional epileptic cortex
E. Aronica et al.
EPILEPSY RESEARCH (2007)
Molecular targets for antiepileptic drug development
Brian S. Meldrum et al.
NEUROTHERAPEUTICS (2007)
Potential new antiepileptogenic targets indicated by microarray analysis in a rat model for temporal lobe epilepsy
Jan A. Gorter et al.
JOURNAL OF NEUROSCIENCE (2006)
The IL-1β system in epilepsy-associated malformations of cortical development
T. Ravizza et al.
NEUROBIOLOGY OF DISEASE (2006)
Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients
Herbert B. Newton et al.
JOURNAL OF NEURO-ONCOLOGY (2006)
Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein
M Gillard et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2006)
Epileptiform activity preferentially arises outside tumor invasion zone in glioma xenotransplants
R Köhling et al.
NEUROBIOLOGY OF DISEASE (2006)
Synaptic vesicle protein 2 enhances release probability at quiescent synapses
KL Custer et al.
JOURNAL OF NEUROSCIENCE (2006)
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
BA Lynch et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Localization of slow wave activity in patients with tumor-associated epilepsy
JC Baayen et al.
BRAIN TOPOGRAPHY (2003)
Epilepsy in low-grade gliomas:: The impact on cognitive function and quality of life
M Klein et al.
ANNALS OF NEUROLOGY (2003)
Levetiracetam: preliminary experience in patients with primary brain tumours
GL Wagner et al.
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY (2003)
Medical management of patients with brain tumors
PY Wen et al.
CURRENT OPINION IN ONCOLOGY (2002)
Microtubule-associated protein 2 (MAP-2) is expressed in low and high grade diffuse astrocytomas
SB Wharton et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2002)
Glioneuronal tumors and medically intractable epilepsy: a clinical study with long-term follow-up of seizure outcome after surgery
E Aronica et al.
EPILEPSY RESEARCH (2001)
The selective vulnerability of nerve cells in Huntington's disease
KA Sieradzan et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2001)
Share Paper
